Effect of CTLA4-Ig on severe asthma (ECSA) study ; Double blind, placebo controlled, phase IIa trial of CTLA4-Ig (abatacept) on severe asthma
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2016
At a glance
- Drugs Abatacept (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ECSA
- 22 Jul 2016 Status changed from active, no longer recruiting to completed.
- 07 Jul 2015 Planned End Date changed to 30 Apr 2016, according to University Hospital Medical Information Network - Japan record.
- 05 Feb 2015 New trial record